
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical is poised for strong growth in the coming years, driven by their refined forecasting methodology and a growing pipeline of new sites, including a major health system. With a strong recurring revenue stream and improving margins, the company is expected to see a 5%-9% increase in revenue in 2026 and achieve positive cash flow. Despite recent commercial execution challenges, their differentiated technology and growing market opportunity make the stock a Buy with a $17 price target based on 2x the 12-24 month revenue estimate.
Bears say
Outset Medical is currently facing commercial headwinds and is making changes to its commercial strategy to improve sales growth following FDA clearance of its TabloCart with Prefiltration. Despite a large market opportunity and the potential for increased revenue as the company ramps up, their reliance on consumable and service contract revenue could limit long-term growth potential. Additionally, with the ongoing search for a new head of sales, there may be a period of uncertainty and potential leadership changes that could impact the company's performance in the short term.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares